Cl
Clementia (Ipsen)
Montreal CAFounded 201050 employees
Private CapbiotechAcquiredRare DiseaseMusculoskeletal
Platform: Palovarotene FOP
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| CLE-2655 | CLE-2655 | Phase 2 | 1 | GPRC5D | Pancreatic CaBladder Ca | ||
| Tirazasiran | CLE-1317 | Phase 1/2 | 2 | BET | WilmsMCL | ||
| CLE-136 | CLE-136 | Phase 3 | 3 | PARP | PAHACC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)